300725 PharmaBlock Sciences
- 34.72
- -1.58-4.35%
PharmaBlock Sciences News
Pharmaceutical Stone Technology (300725): Profitability is under short-term pressure, orders continue to improve
Yakishi Technology (300725): The gradual resumption of business with in-hand orders is expected to gradually reach an inflection point
Yakishi Technology (300725): Ongoing orders are growing steadily, and the CDMO business continues to empower global customers
Pharmaceutical Stone Technology (300725) Annual Report Review Report: CDMO sector grows steadily, profit side is under pressure in the short term
Pharmaceutical Stone Technology (300725): CDMO's steady development continues to consolidate its technical advantages
Pharmaceutical Stone Technology (300725): Profit side is under phased pressure to continue to expand the field of new chemical physical pharmaceuticals
Pharmaceutical Stone Technology (300725): Demand contraction affects growth rate in many ways to respond to industry changes
Open Source Securities released a research report on April 25 stating that it gave Yakishi Technology (300725.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is under pressure due to multiple factors, and the number of s
Yakishi Technology (300725): Steady revenue growth and profitability is expected to improve
Yakishi Technology (300725): Customer pipeline continues to expand, CDMO business continues to grow
Yakishi Technology (300725): Front-end business gradually recovers, waiting for the industry to gradually reach an inflection point
Yakushi Technology (300725): Steady growth in revenue, short-term pressure on profit
Yakushi Technology (300725): Steady growth in the first three quarters, fluctuations in gross margin and increased financial expenses disrupted profits
Yakushi Technology (300725): Q3 maintains a steady pace, promotes internal adjustments and enhances strength
Yakushi Technology (300725): Looking forward to profit margin restoration and continuing to strengthen the technology platform
Yakushi Technology (300725) 2023 Interim Report Review: Revenue Maintains Steady Growth and Capacity Building Continues to Advance
Yakushi Technology (300725) 2023 Interim Report Review Report: Steady Revenue Growth and Temporary Profit Pressure
Yakushi Technology (300725) Company Information Update Report: Performance Meets Expectations Due to Multiple Factors, Continued Pressure on Profits in the Short Term
PHARMABLOCK SCIENCES(300725):REVENUE MAINTAINS GROWTH DESPITE PRESSURE PROFIT UNDER SHORT-TERM PRESSURE
Medicinal Stone Technology (300725): Revenue continues to grow under pressure and profits are under pressure in the short term
Analysis
Price Target
No Data
No Data